Stock: Zoetis (ZTS)Top Management and Board of DirectorsTop ManagementTop Management [Ten top executives with tenure > 12 yrs]
Board Of DirectorsBoard Of Directors [Ten directors with tenure > 10 yrs]
Independent Ratings of Directors+ Kristin Peck- Fortune Businessperson of the Year Ranking: Kristin Peck was ranked 15 in the Fortune Businessperson of the Year's list of top 20 Businesspersons for 2020. Profiles of Top ManagementKristin PeckCEO & Director Kristin Peck was appointed Chief Executive Officer of Zoetis in January 2020. In this role, she leads the world's leading animal health company, a Fortune 500 organization with approximately $6 billion in annual revenue and 10,000 employees worldwide. Ms. Peck is also a member of the Zoetis Board of Directors. Prior to becoming CEO, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at Zoetis. Ms. Peck helped usher Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in many roles at the company including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as executive vice president, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer's Executive Leadership Team. In this role, she was responsible for the evaluation of strategic alternatives for Pfizer's Animal Health and Nutrition businesses - paving the way for a public animal health company and attractive investment opportunity. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O'Connor Group and J.P. Morgan. Ms. Peck is a member of the Business Roundtable, and also serves on the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. She previously served as a member of the Thomson Reuters' Board of Directors. As a recipient of the 2019 Feather in Her Cap Award, Ms. Peck has been recognized for her leadership and contributions to the animal health industry, and her work in mentoring women and helping them advance their careers in animal health. Ms. Peck holds a bachelor's degree from Georgetown University and an MBA from Columbia Business School. Fortune Businessperson of the Year Ranking: Kristin Peck was ranked 15 in the Fortune Businessperson of the Year's list of top 20 Businesspersons for 2020. Michael McCallister Non-Executive Chairman Former Chairman of the Board and CEO of Humana Inc. from 2010 to 2013. Humana is a health care company that offers a wide range of insurance products and health and welfare services. Mr. McCallister joined Humana in 1974, and was its Chief Executive Officer from February 2000 until his retirement on December 31, 2012. During his tenure as CEO, Humana gained a reputation as one of the industry's leading people-focused innovative companies, leveraging products, processes and technology to help individuals take control of their own health. Mr. McCallister served for many years on the board of the Business Roundtable and is past Chairman of its Health and Retirement Task Force. He is currently on the boards of AT&T, where he serves on the audit committee, and Fifth Third Bank. Mr. McCallister holds a bachelor's degree in accounting from Louisiana Tech University and an MBA from Pepperdine University. Mr. McCallister's senior management experience in the health care industry, along with his public company board experience, make him a valuable member of our Board. Shareholder Value: Creation of shareholder value in Zoetis: Month of appointment: June 2013 In the last 10 years the average annualized return to shareholders was 13.4%. The present value of $1,000 (PV1000) invested 10 years ago is now $3,531, a gain of $2,382 and dividend reinvested of $149. Wetteny N. Joseph CFO & Executive Vice President Wetteny Joseph is executive vice president and Chief Financial Officer of Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, he is responsible for overseeing the financial management, planning, operations and indirect procurement functions. Mr. Joseph also has oversight responsibility for the company's Human Health Diagnostics business. During his career, he has worked across diverse and complex businesses; led finance functions, business units and business development; and managed relationships with stakeholders from customers and suppliers to investors. Mr. Joseph joined Zoetis in June 2021, after having spent 13 years in executive positions at Catalent, a global leader in pharmaceuticals, biologics and consumer health products. Before joining Zoetis, he was senior vice president and chief financial officer of Catalent for three years, overseeing accelerated financial growth and value creation at the company through transformational acquisitions and organic capital deployment. He first joined Catalent in 2008 as corporate controller and held several senior finance positions until October 2015, when he was named president of the Clinical Supply Services business, responsible for $400 million in annual sales from the global business unit. Robert J. Polzer Executive Vice President Robert J. Polzer, Ph.D., is Executive Vice President and President, Research and Development at Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, he is responsible for leading a global organization that discovers, develops and registers new products, including genetic testing, vaccines, diagnostics and therapeutics that help predict, prevent, detect and treat animal health conditions in the eight core species that Zoetis serves. He also leads teams that develop new sensor and biodevice instruments to complement the core portfolio. Dr. Polzer joined Zoetis in 2015 as the Head of Global Therapeutics where he led research and development activities to discover and register innovative solutions. He has been pivotal in advancing the company's recent innovations, including monoclonal antibody platforms across species and therapeutic areas and a growing portfolio of companion animal parasiticides. He has also fostered external innovation collaborations with Colorado State University, which is involved in identifying new companion animal allergy and dermatology solutions and developing new immunotherapies that could pave the way for alternatives to antibiotics in food-producing animals, as well as with Regeneron to explore the connections between animal and human health. Prior to joining Zoetis, he spent over 20 years with Pfizer in drug metabolism research with roles of increasing organizational impact including global leadership of Pharmacokinetics, Dynamics, and Metabolism. He has a bachelor's degree in Chemistry and German Literature from Muhlenberg College and earned his Ph.D. in Medicinal Chemistry at Purdue University. Nick Ashton Executive Vice President Nick Ashton is Executive Vice President and President, Global Manufacturing and Supply at Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, he oversees the company's network of approximately 29 Zoetis manufacturing sites and 200 third-party manufacturers around the world. Mr. Ashton joined Zoetis in 2020 as head of Global External Supply, where he led all aspects of the company's global external manufacturing network, overseeing 140 Contract Manufacturing Organizations (CMOs) to keep pace with customer demand. Mr. Ashton brings more than 30 years of global experience in areas of production, supply chain, external manufacturing, procurement, network strategy and execution for major international companies including GSK, Babcock International and Merck. Mr. Ashton earned his bachelor's degree in Chemical Engineering with Biochemical Engineering from Birmingham University. Roxanne Lagano Executive Vice President & Corporate Secretary Roxanne Lagano was appointed executive vice president and chief human resources officer at Zoetis in November 2012. In this role, she is responsible for the company's worldwide human resources management. In 2015, Ms. Lagano was also given responsibility for the corporate communications function. Prior to joining Zoetis, Ms. Lagano was senior vice president, Global Compensation, Benefits and Wellness for Pfizer. In that role, Ms. Lagano was responsible for the design and implementation of Pfizer's compensation and employee benefit programs around the globe. She was also responsible for Pfizer's wellness strategies, including the Healthy Pfizer program, and for the human resources aspects of the company's merger, acquisition and divestiture activities. Ms. Lagano joined Pfizer in 1997 as manager, Tax Planning, after specializing in employee benefits, executive compensation and mergers and acquisitions at Schulte, Roth and Zabel, LLP, a New York law firm. After joining Pfizer's legal division in 1999, Ms. Lagano joined Pfizer's Human Resources organization in 2000. During her time in HR for Pfizer, Ms. Lagano held various positions of increasing responsibility, including senior director of business transactions (HR) and senior director, employee benefits. Ms. Lagano holds a Juris Doctor degree from Hofstra University School of Law and a Bachelor of Science degree from Long Island University. Shareholder Value: Creation of shareholder value in Zoetis: Year of appointment: 2012 In the last 10 years the average annualized return to shareholders was 13.4%. The present value of $1,000 (PV1000) invested 10 years ago is now $3,531, a gain of $2,382 and dividend reinvested of $149. Brannan Jamie Executive Vice President & Chief Commercial Officer Jamie Brannan is Executive Vice President and President of International Operations and Aquaculture at Zoetis, the world leader in animal health. In this role, he's responsible for commercial operations in over 120 international markets and the global aquaculture business. As a senior business leader in human and animal health for over a decade, Mr. Brannan has consistently demonstrated his ability to build diverse teams with the agility to adjust through fast, evolving business conditions across international markets. Mr. Brannan previously served as President, Zoetis International Operations from June 2021 until November 2022, where his strong leadership with a focus on performance and commercial excellence advanced the business significantly. Prior to leading International Operations, he served as Senior Vice President of Zoetis' Northern Europe Cluster from October 2016 until June 2021. In this role he was responsible for sales, marketing, commercial operations for the business in the UK, Ireland and Nordic markets. Keith Sarbaugh Executive Vice President & Chief Technology Officer Keith Sarbaugh is Executive Vice President, Chief Digital & Technology Officer at Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, he oversees the company's technology and digital strategy, including IT, cybersecurity, data analytics, and AI to drive innovation through digital solutions and data insights. He also manages Zoetis' Global Customer Experience program. Previously, Mr. Sarbaugh was Zoetis' Chief Information Officer from March 2023 to November 2024, where he directed enterprise technology, infrastructure delivery, and operations. Keith joined Zoetis in March 2023, bringing 23 years of experience in Tech and Digital leadership roles. Prior to joining Zoetis, he was VP, Information Technology at Biogen, overseeing all aspects of Infrastructure, IT Operations, and Enterprise Architecture globally. Previously, he held various corporate leadership roles at Eli Lilly and Company, including Head of IT Infrastructure and Enabling Functions and Regional CIO for Lilly's U.S. Commercial, Southeastern and Central Eastern European businesses. Mr. Sarbaugh holds a bachelor's degree in information systems from Purdue University and an MBA from Duke University's Fuqua School of Business. Julie Fuller Executive Vice President & Chief Human Resources Officer Julie Fuller is the Executive Vice President and Chief Human Resources Officer at Zoetis, the world's leading animal health company and a member of the Fortune 500. In this role, she leads the company's worldwide human resources team and strategy and is responsible for ensuring an exceptional colleague experience and award-winning workplace for 14,000 colleagues globally. Ms. Fuller is also responsible for the Global Operations function at Zoetis. Prior to joining Zoetis, Ms. Fuller was the Chief People Officer of PVH Corp., one of the largest global fashion and apparel companies in the world, with over 27,000 employees across 40 countries. She joined PVH in 2020 as a member of the senior leadership team, leading the global Human Resources function, including Talent Management and Development, Executive Development, Total Rewards, HR Operations, Organizational Effectiveness and Inclusion & Diversity. In this role she also had oversight of the PVH Foundation. Prior to PVH, Ms. Fuller was the Vice President of Global Talent and Organizational Effectiveness for Nike, Inc. In this role, her team was responsible for creating an aligned and effective organization, enabling 74,000 employees to build their careers, continually grow and develop, and cultivate a strong pipeline of diverse and capable leaders to take Nike into the future. She previously led HR for Nike's North America and Emerging Markets geographies. Prior to Nike, Ms. Fuller held key HR leadership positions at Avon and PepsiCo. Ms. Fuller has extensive experience in establishing and nurturing talented high-performing teams for large multinational companies. Her experience includes a mix of broad HR leadership and specialist roles focusing on organizational transformation, leadership development, enterprise talent management, succession planning, employee engagement and performance, and diversity and inclusion. Ms. Fuller holds a Ph.D. in Industrial and Organizational Psychology from Bowling Green State University, and a B.A. in Psychology from the University of New Hampshire. Profiles of Board of DirectorsAntoinette (Tonie) LeatherberryDirector Antoinette (Tonie) Leatherberry has served as a member of the Zoetis Board since December 2020. Ms. Leatherberry retired from Deloitte, an industry-leading consulting, audit, tax and advisory services company, in 2020 after culminating a career of working with Fortune 500 companies on complex information technology transformations and operational issues. She has authored numerous articles and publications on information technology and governance, and was named to the National Association of Corporate Directors NACD Directorship 100 in 2019 and 2020. Ms. Leatherberry has been recognized in such publications as Consulting Magazine's Top 25 Consultants and Black Enterprise's Most Powerful Women in Business. She has also devoted much of her professional life to creating opportunities for women and people of color. At Deloitte, Ms. Leatherberry was the principal architect of The Board Leadership Forum and the NextGen CEO Academy, which helped place more than 70 Black leaders into executive level and board roles. She currently serves as chair of the Executive Leadership Council (ELC), a preeminent association of Black business leaders, which focuses on board and executive leadership development, philanthropy, skills and talent development. Ms. Leatherberry serves on the Board of Directors for the American Family Insurance Mutual Holding Company, the Widener University Board of Trustees, and the Boston University Board of Trustees. She holds a bachelor's degree in Mechanical Engineering from Boston University and an MBA in Operations Management and Supervision from Northeastern University, and is pursuing a doctorate in higher education policy at Widener University. Broadhurst Vanessa Director Ms. Broadhurst is currently Executive Vice President, Global Corporate Affairs at Johnson & Johnson, where she is a member of the company's Executive Committee. At Johnson & Johnson, Ms. Broadhurst leads the company's global marketing, communication, design and philanthropy functions, in addition to having oversight of Johnson & Johnson Health & Wellness Solutions. Prior to her appointment to the Executive Committee in 2022, Ms. Broadhurst was Company Group Chairman, Global Commercial Strategy for Pharmaceuticals. In that role, she led a team focused on commercialization and launch strategies across the company's broad pipeline of products, spanning six therapeutic areas. Additionally, she had oversight of global value and access, global commercial data sciences, and global medical affairs across the portfolio of pharmaceutical products. Paul M. Bisaro Independent Director President and Chief Executive Officer of Impax Laboratories, a specialty pharmaceutical company, since March 2017. Mr. Bisaro was the Executive Chairman of the board of directors of Allergan plc (formerly Actavis plc) from July 2014 to October 2016. Until June 2014, Mr. Bisaro served as Board Chairman, President and Chief Executive Officer of Actavis, a global pharmaceutical company, (formerly Watson Pharmaceuticals). He was appointed President, Chief Executive Officer and a member of the board of Watson Pharmaceuticals in September 2007; and was later appointed Chairman of the board of Watson Pharmaceuticals in October 2013. Prior to joining Watson, Mr. Bisaro was President, Chief Operating Officer and a member of the board of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company, from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President - Strategic Business Development. Prior to joining Barr, Mr. Bisaro was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro currently serves on the board of directors of Allergan plc and Impax Laboratories, and on the Board of Visitors of The Catholic University of America's Columbus School of Law. Mr. Bisaro previously served on the board of Zimmer Biomet Holdings, Inc., a world leader in musculoskeletal health solutions, from 2013 to 2017. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from The Catholic University of America in Washington, D.C. Mr. Bisaro's business, management and leadership experience, his understanding of the pharmaceutical industry, and his public company board experience make him a valuable member of our Board. Shareholder Value: Creation of shareholder value in Zoetis: Date of appointment: May 01, 2015 In the last 10 years the average annualized return to shareholders was 13.4%. The present value of $1,000 (PV1000) invested 10 years ago is now $3,531, a gain of $2,382 and dividend reinvested of $149. Willie M. Reed Independent Director Dean of the College of Veterinary Medicine at Purdue University since 2007. Dr. Reed has more than 30 years of experience in animal health and veterinary medicine, gained during his tenure at Purdue University and Michigan State University, and as a Diplomate of the American College of Veterinary Pathologists and Charter Diplomate of the American College of Poultry Veterinarians. Dr. Reed has served as President of the Association of American Veterinary Medical Colleges, President of the American Association of Veterinary Laboratory Diagnosticians, President of the American Association of Avian Pathologists and Chair of the American Veterinary Medical Association Council on Research. He has served on a number of committees for the National Institutes of Health and the United States Department of Agriculture. Dr. Reed has a Doctor of Veterinary Medicine degree from Tuskegee University, and a Ph.D. in Veterinary Pathology from Purdue University. Dr. Reed's medical expertise, his expertise in veterinary medicines and vaccines and his thought leadership in the animal health community make him a valuable member of our Board. Dr. Mark Stetter Independent Director Dr. Stetter currently serves as Dean of the University of California, Davis School of Veterinary Medicine. In this role he oversees all aspects of the school including education, research, veterinary hospitals, animal health diagnostic labs, centers and institutes. He served as Dean and Professor at the College of Veterinary Medicine and Biomedical Sciences at Colorado State University from 2012 until 2021. Prior to joining higher education, Dr. Stetter held various senior roles at The Walt Disney Company including Director of Animal Operations and Director of Animal Health. He also served in various capacities, including zoo and wildlife veterinarian, at The Bronx Zoo/Wildlife Conservation Society and the Audubon Nature Institute. Dr. Stetter has held leadership roles within national organizations, including serving as Director, PetSmart Charities Board, Treasurer for the American Association of Veterinarian Medical Colleges, President of the American College of Zoological Medicine, Chair for the Wildlife Scientific Advisory Board with Morris Animal Foundation and Chair of the research committee with the American Association of Zoo Veterinarians. He holds a Doctor of Veterinary Medicine and a Bachelor of Science degree in biochemistry and chemistry from the University of Illinois at Champaign-Urbana. Sanjay Khosla Independent Director Former Executive Vice President and President, Developing Markets of Mondelez International from 2007 to 2013. Mr. Khosla brings more than 35 years of international business experience from his career with food, beverage and consumer product leaders such as Mondelez, Kraft and Unilever, where he managed various business units, particularly in developing markets. As President, Kraft Foods, Developing Markets (now Mondelez International) from 2007 to 2013, Mr. Khosla transformed the $5 billion business into a $16 billion business, while significantly improving profitability. He also has animal health experience from his three-year tenure from 2004 to 2007 as Managing Director of Fonterra Brands and Food Service, a multinational dairy cooperative based in New Zealand. Mr. Khosla serves on the board of Iconix Brand Group, Inc., a company that licenses and markets a portfolio of consumer brands. From October 2008 until June 2015, he served on the board of Best Buy, Inc., a specialty retailer of consumer electronics, personal computers, entertainment software and appliances, and from 2002 to 2017, he served on the board of NIIT, Ltd., a company involved in technology-related educational services. Mr. Khosla holds a bachelor's degree in electrical engineering from the Indian Institute of Technology in New Delhi. Mr. Khosla also completed the Advance Management Program at Harvard Business School. Mr. Khosla is currently a senior fellow and adjunct professor at the Kellogg School of Management, Northwestern University and a Senior Advisor for the Boston Consulting Group. Mr. Khosla is also CEO of Bunnik LLC, a management consulting firm. Mr. Khosla's international business and management experience, along with his public company board experience, make him a valuable member of our Board. Gregory Norden Independent Director Former Chief Financial Officer of Wyeth. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co. Mr. Norden currently serves on the boards of Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products; NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products; Royalty Pharma, a leader in the acquisition of revenue-producing intellectual property; and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015; Lumara Health, where he served until 2014; and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services. Mr. Norden's background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, along with his public company board experience, make him a valuable member of our Board. Gavin D. K. Hattersley Independent Director Gavin D.K. Hattersley currently serves as the President and Chief Executive Officer at Molson Coors Beverage Company, a global brewing beverage company (since September 2019). Prior to his current position, Mr. Hattersley served as chief executive officer of MillerCoors, the former U.S. division of Molson Coors, since September 2015. Prior to joining MillerCoors, Mr. Hattersley served as chief financial officer of Molson Coors from June 2012 to September 2015. From July 2008 to June 2012, Mr. Hattersley served as executive vice president and chief financial officer of MillerCoors. He also served as senior vice president of finance for Miller Brewing Company from October 2002 to July 2008. Prior to joining Miller Brewing Company Mr. Hattersley held several financial management positions with SAB Limited of Johannesburg, South Africa, before becoming chief financial officer in 1999. Prior to joining SAB Limited in 1997, Mr. Hattersley spent almost 10 years with Barloworld Limited in various finance positions. In addition to his service on the Zoetis Board of Directors, Mr. Hattersley currently serves as a member of the Board of Directors of Molson Coors Beverage Company. Mr. Hattersley holds an honors degree in accounting science and a bachelor's degree from the University of South Africa. Mr. Hattersley's senior management experience, including as a current chief executive officer and former chief financial officer, along with his international business and public company board experience, make him a valuable member of our Board. Louise Parent Independent Director Louise Parent has been a member of our board since August 2013. From 2003 through 2013, Ms. Parent served as Executive Vice President and General Counsel of American Express Company.Since early 2014, Ms. Parent has served as Of Counsel at the law firm of Cleary Gottlieb Steen & Hamilton LLP.Ms. Parent brings deep experience in corporate governance and board matters, gained during her tenure with American Express, where she worked extensively with the Audit, Compensation, and Nomination and Governance committees in her role as General Counsel. Ms. Parent also served on the operating committee and global management team of American Express from 2003 through 2013, was a member of the board of American Express Centurion Bank through 2013 and served on the Supervisory Board of Deutsche Bank AG from 2014 to 2018.Ms. Parent currently serves on the board of Fidelity National Information Services Inc., a global financial services technology company. Shareholder Value: Creation of shareholder value in Zoetis: Year of appointment: 2013 In the last 10 years the average annualized return to shareholders was 13.4%. The present value of $1,000 (PV1000) invested 10 years ago is now $3,531, a gain of $2,382 and dividend reinvested of $149. Frank A. D'Amelio Independent Director Frank D'Amelio is the former Executive Vice President and Chief Financial Officer of Pfizer Inc., a global pharmaceutical company (June 2020 to May 2022), and a member of Pfizer's Senior Executive Leadership Team. Mr. D'Amelio currently serves as a CFO in residence at the Deloitte CFO Academy. From June 2020 through December 2021 Mr. D'Amelio also served as Pfizer's Executive Vice President, Global Supply and Business Operations. Mr. D'Amelio previously served as Pfizer's Executive Vice President, Business Operations and Global Supply and Chief Financial Officer from October 2018 until June 2020 and Executive Vice President, Business Operations and Chief Financial Officer from December 2010 to September 2018. He joined Pfizer in September 2007 and held various positions, including Senior Vice President and Chief Financial Officer. During Mr. D'Amelio's tenure at Pfizer, he led many acquisitions and partnerships valued at nearly $200 billion, including numerous transformative transactions, such as the acquisition of Wyeth as well as the divestitures of the animal health, consumer health and mature products businesses, and oversaw the company's information technology function and global supply chain. From November 2006 to August 2007, Mr. D'Amelio was the Senior Executive Vice President of Integration and Chief Administrative Officer at Alcatel-Lucent, S.A., a global telecommunications equipment company. From January 2006 to November 2006, Mr. D'Amelio was the Chief Operating Officer of Lucent Technologies, with responsibility for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources and labor relations. From May 2001 until January 2006, he was appointed Executive Vice President, Administration, and Chief Financial Officer of Lucent. |